Atea Pharmaceuticals, Inc.

NASDAQ•AVIR

CEO: Dr. Jean-Pierre Sommadossi Ph.D.

板块: Healthcare

行业: Biotechnology

上市日期: 2020-10-30

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

联系方式

225 Franklin Street, Suite 2100, Boston, MA, 02110, United States

857-284-8891

ateapharma.com

市值

$414.07M

市盈率 (TTM)

-2.8

17.8

股息率

52周最高

$5.34

52周最低

$2.46

52周范围

99%

排名45Top 56.8%

3.6

F-Score

改良版 Piotroski 分析

基于 7 年期基本面

疲弱 • 3.6 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2019-2025

财务仪表盘

Q3 2025 数据

营业收入

$0.00+0.00%

近4季度走势

每股收益

-$0.53+43.24%

近4季度走势

自由现金流

-$40.38M+75.28%

近4季度走势

2026 Annual 财报亮点

核心亮点

HCV Phase 3 Trials Progressing C-BEYOND fully enrolled; C-FORWARD enrollment expected complete YE 2026; NDA targeted March 2027.

Net Loss Narrows Significantly Net loss decreased $10.0 M to $(158.3) M in 2025; R&D spend increased slightly to $148.0 M.

Cash Position Strong Cash, equivalents, and securities totaled $301.8 M on December 31, 2025, sufficient through 2027.

Workforce Reduction Completed 25% workforce reduction in Q1 2025 expected to yield $15.0 M aggregate cost savings through 2027.

关注风险

High Dependence on HCV Candidate Business highly dependent on successful HCV regimen development, approval, and commercialization; failure causes significant harm.

Need Substantial Future Financing Expect substantial operating expenses; failure to obtain necessary capital could delay or terminate product development efforts.

Regulatory Approval Unpredictable Regulatory approval processes are lengthy, expensive, and inherently unpredictable; failure to obtain approval seriously harms business.

Intellectual Property Litigation Risk Facing patent challenges from Gilead Sciences regarding bemnifosbuvir; adverse ruling requires licensing or halts commercialization.

前瞻展望

Targeting HCV NDA Submission Targeting submission of HCV regimen NDA to FDA in March 2027, pending successful completion of Phase 3 trials.

Initiate HEV Phase 1 Study Anticipate initiating clinical development of AT-587 for chronic HEV with a first-in-human Phase 1 study mid-2026.

Cash Funds Operations Through 2027 Current cash position of $301.8 M is expected to fund planned operations through the end of 2027.

Merck Milestone Payment Anticipated Next $10.0 M Merck milestone payment anticipated due upon acceptance of HCV regimen NDA in H1 2027.

同行对比

营业收入 (TTM)

VNDA

$216.11M

+8.7%

ARCT

$78.24M

-43.5%

ENTA

$66.98M

+0.6%

毛利率 (最新季度)

ARCT

408.3%

-19.5pp

ENTA

100.0%

+0.0pp

PRQR

100.0%

+0.0pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
VTYX	$1.00B	-9.4	-48.1%	4.7%
OMER	$814.65M	-6.3	57.3%	103.2%
ALLO	$519.13M	-2.4	-57.8%	19.4%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

N/M

营收波动较大

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年5月11日

每股收益:-

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据